Dataset Information

Subcutaneous ureteral bypass device placement in 81 cats with benign ureteral obstruction (2013-2018).

ABSTRACT:

Background

Benign ureteral obstructions (BUOs) present a therapeutic challenge in cats.

Hypothesis/objectives

The purpose of this study was to determine the outcome and complications associated with placement of subcutaneous ureteral bypass (SUB) device in cats.

Animals

Eighty-one client-owned cats (117 kidneys) with BUO treated by placement of a SUB.

Methods

Retrospective study. Medical records of cats with BUO and treated by SUB device placement between 2013 and 2018 were reviewed. Outcome and complications were documented.

Results

Hospital discharge rate was 94% (76/81). Serum creatinine on admission and at the time of discharge was 5.3 mg/dL (range, 1.2 to >15 mg/dL) and 2.1 mg/dL (range, 1.1-12.5 mg/dL), respectively. Luminal obstructions were documented in 17% (18/109) of the SUB devices of 16 cats discharged from the hospital. Infection was documented in 26% (20/76) of discharged cats. Kink of the device was documented in 10% (12/117) of devices. Time to luminal obstruction and kink were 204 days (range, 21-1678 days) and 58 days (range, 2-601 days), respectively. Fourteen of 81 (17%) cats required a revision surgery in order to restore patency of the device. At the time of writing, 53% (43/81) of cats were alive, with a mean survival time of 821 days (range, 1-2170 days) after surgery. Of those that died, 52% (20/38) died of urinary related causes.

Conclusion and clinical importance

This study suggests that SUB device placement is associated with good outcomes and could be considered for the treatment of BUO in cats.

SUBMITTER: Wuillemin F

PROVIDER: S-EPMC8692180 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundUreteral obstruction caused by extrinsic compression is often associated with intra-abdominal cancers. Internal drainage with ureteral stents is typically the first-line therapy to relieve such obstructions. Novel designs of ureteral stents made of different materials have been invented to achieve better drainage. In this study, we described the functional outcomes of a Resonance metallic ureteral stent (Cook Medical, Bloomington, Indiana, USA) in patients with malignant ureteral obstruction and compare the functional duration of Resonance stents with regular polymeric stents in the same cohort.MethodsCancer patients who received polymeric stents and subsequent Resonance stents for ureteral obstruction between July 2009 and November 2012 were included in a chart review. Stent failure was detected by clinical symptoms, imaging studies, and renal function tests. The functional durations of each stent were calculated, and possible factors affecting stent patency were investigated.ResultsA total of 50 stents were successfully inserted into 50 ureteral units in 42 patients with malignant ureteral obstruction. There were 7 antegrade stents and 43 retrograde stents. There were no major complications. Stent-related symptoms were similar in both kinds of stents. After polymeric stents were replaced with Resonance metallic stents, hydronephrosis subsided or remained stable in 90% (45/50) of the ureteral units. Serum creatinine decreased or remained stable in 90% (38/42) of these patients. The Resonance stent exhibited a mean increase in functional duration of 4 months compared with the polymeric stents (p<0.0001), and 50% (25/50) of the Resonance stents exhibited a significant increase in functional duration (more than 3 months). Pre-operative serum creatinine < 2 was associated with a substantial increase in stent duration.ConclusionsResonance stents are effective and safe in relieving malignant ureteral obstructions after polymeric stents failure. Resonance stents can provide a longer functional duration than polymeric stents and should be offered as an option for internal drainage.

Project description:Although the primary organ has been the subject of intense investigation in the field of organ fibrosis over the past several decades, the presence of lymph node fibrosis due to persistent activation of the immune response in its partner organ remains largely unknown. Previously, we demonstrated that activation of the immune response following ischemia-reperfusion injury (IRI) and crescentic glomerulonephritis (CGN) in the kidney was associated with extracellular matrix (ECM) production by fibroblastic reticular cells (FRCs) of the kidney-draining lymph node (KLN). Here, we sought to determine whether FRCs in the KLN become similarly fibrogenic following unilateral ureteral obstruction (UUO) of the kidney. We subjected 6-8-week-old C57BL/6J mice to UUO for 2, 7, and 14 days. We examined the microarchitecture of the kidney and KLN by immunofluorescence staining at each timepoint, and we quantified immune cell populations in the KLN by flow cytometry. The contralateral kidney unaffected by UUO and its partner KLN were used as controls. We found through immunofluorescence staining that FRCs increased production of ECM fibers and remodeled the microarchitecture of the UUO KLN, contributing to fibrosis that mirrored the changes in the kidney. We also observed by flow cytometry that the populations of CD11b+ antigen-presenting cells, CD11c+ dendritic cells, and activated CD4+ and CD8+ T cells were significantly higher in the UUO KLN than the KLN draining the unaffected contralateral kidney. Expression of the TGFβ/TGFβR signaling pathway was upregulated and colocalized with FRCs in the UUO KLNs, suggesting a possible mechanism behind the fibrosis. Both release of ureteral ligation at 2 days following UUO and depletion of FRCs at the time of injury onset halted the progression of fibrosis in both the kidney and the KLN. These findings for the first time highlight the association between fibrosis both in the kidney and the KLN during UUO, and they lay the groundwork for future studies that will investigate more deeply the mechanisms behind the connection between FRCs and KLN fibrosis.